GlassScriptPhysician profile
Kyle D Krotzer
NPI 1356997373
$622.49
in general payments reported to CMS, 2019-2025
15 companies · $549 in 2025
The $549 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $73.86 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $131.23 | 2022-2025 | Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $99.19 | 2025 | |
| Exact Sciences Corporation | $51.53 | 2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $51.21 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.28 | 2025 | Xifaxan |
| Baxter Healthcare | $38.05 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Teva Pharmaceuticals USA, INC. | $36.92 | 2025 | Austedo Xr |
| Dexcom, INC. | $33.43 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $32.69 | 2025 | |
| Abbvie INC. | $23.37 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $18.61 | 2025 | Farxiga |
| Recordati_rare_diseases_inc. | $17.68 | 2025 | Isturisa |
| Glaxosmithkline, LLC. | $16.70 | 2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $15.49 | 2025 | Zepbound, Mounjaro |
| Alkermes, INC. | $15.11 | 2025 | Aristada, Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Krotzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.